Ignite Creation Date:
2025-12-25 @ 2:37 AM
Ignite Modification Date:
2026-05-16 @ 4:04 AM
Study NCT ID:
NCT05310734
Status:
RECRUITING
Last Update Posted:
2025-02-14
First Post:
2022-03-09
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
PK and Safety Study of Natroba Topical Suspension 0.9% in Subjects 1 Month to 3 Years 11 Months of Age With Scabies
Sponsor:
Cipher Pharmaceuticals Inc.
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Scabies | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | Pharmacokinetics | View |
| None | PK | View |
| None | Pharmacokinetics and Safety Study of Spinosad | View |
| None | PK and Safety Study of Spinosad | View |
| None | Spinosad PK and Safety Study | View |
| None | Safety | View |
| None | Pharmacokinetic and Safety Study of Natroba | View |
| None | PK and Safety Study of Natroba | View |
| None | Natroba PK and Safety Study | View |